Satisfactory performance supporting Coloplast's growth ambitions

Coloplast generated revenue of DKK 8,665 million and 6% organic growth in the first nine months of the 2012/13 financial year. Q3 organic growth was 7%.

 

EBIT was up by 14% to DKK 2,699 million. The EBIT margin was 31% against 29% in the first nine months last year. The net profit for the period was up by 24% to DKK 1,962 million.

“I'm very pleased with the financial results we are announcing today. We're growing in allbusiness areas and in all regions, and our performance supports our ambition to accelerate our growth,” says Coloplast CEO Lars Rasmussen.

Sales growth by business area was as follows: Ostomy Care 7%, Continence Care 6%,Urology Care 9% and Wound & Skin Care 4%.

“I'm quite pleased with our sales performance in the Ostomy Care business, especially in the European market. Our growth in the US market was very satisfactory and especially our two smaller business areas, Urology Care and Wound Care, delivered good results despite challenging market conditions. In other markets, Brazil and China both delivered a very good growth performance,” says Lars Rasmussen.

 

Coloplast is increasing its global production capacity

Coloplast will be investing around DKK 130 – 150 million over the next two years to expand its factory in Nyírbátor, Hungary.

“We're growing year by year and need therefore more space and more production capacity,”says Lars Rasmussen, and he continues: “We've decided to expand one of our two factories in Hungary because we consider that to be the most viable solution. The central location in Europe is important because the vast majority of our sales are in Europe.”

Currently, Coloplast has production facilities in Denmark, Hungary, China, France and the USA. New products are manufactured at the two innovation factories in Mørdrup and Thisted, Denmark in a close collaboration with the global marketing and R&D departments at the Danish headquarters in Humlebæk. The factories in Hungary and China are designed specifically for volume production.

 

For further information, click here to read the Q3 Interim Report.